Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program. Go to Publication You Might Also Like Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015 Evaluation of light emitting diode-based fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. April 10, 2011 Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. July 2, 2018 Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. July 6, 2009 Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. January 31, 2009
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015
Evaluation of light emitting diode-based fluorescence microscopy for the detection of mycobacteria in a tuberculosis-endemic region. April 10, 2011
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. July 6, 2009
Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. January 31, 2009